gynecologic cancer edward l. cohen, md chief section of gynecology department of surgery va palo...
Post on 28-Dec-2015
217 Views
Preview:
TRANSCRIPT
GYNECOLOGIC CANCER
Edward L. Cohen, MDChief Section of Gynecology
Department of SurgeryVA Palo Alto Healthcare System
AndAssociate Clinical Professor OB/Gyn
Stanford UniversitySchool of Medicine
GYNECOLOGIC CANCER
Annual Meeting
NOVA
Milpitas California
26 January 2008
GYNECOLOGIC CANCER
Endometrium
Most common gyn cancer in the US
6% of all cancer in women
2-3% lifetime risk
GYNECOLOGIC CANCER
Endometrium
Age Mean is 61 yrs.
Menopausal 75-80%
Pre-menopausal 20-25%
~5% <40 yrs old.
GYNECOLOGIC CANCER
Endometrium
Types Endometrioid 89% Adeno-squamous 4% Papillary Serous 3% Clear cell
GYNECOLOGIC CANCER
Endometrium
Prognosis depends on cell type, grade, and stage.
Overall, endometrioid has a better prognosis than adeno-squamous, papillary serous, or clear cell.
GYNECOLOGIC CANCER
Endometrium Increased risk factors Age Estrogen Obesity Diabetes (Type II) PCOS Late menopause (>55yr) (Define menopause) Nulliparity Tamoxifen Hereditary nonpolyposis colorectal cancer (HNPCC)
GYNECOLOGIC CANCER
Endometrium Risk factors and RR Estrogen 10 (3-15) Obesity 3-4 Diabetes 2.8 PCOS 3 Late menopause 2 Nulliparity 2 Tamoxifen Increase of 6/1000 (Decrease breast 121/1000) HNPCC 40-60% lifetime risk
GYNECOLOGIC CANCER
Endometrium Decreased risk factors:
--Add progestin to ERT (RR=1) --Use of OCPs for at least 12 mos (RR=0.5). Effect lasts at least 15 years. --Exercise—decreases obesity and favorable changes in immune function and sexual and metabolic hormone levels and growth factors --Diet of fresh fruit, vegetables, whole grain foods
GYNECOLOGIC CANCER
Endometrium—Risk Factors Estrogen (unopposed) Exogenous ERT Tamoxifen Endogenous Chronic anovulation PCOS and obesity
GYNECOLOGIC CANCER
Endometrium
Exogenous estrogen
ERT effects can be reversed by
addition of a progestin.
Tamoxifen and SERMs
Receptors differ in breast and
endometrium. Stimulates endom.
GYNECOLOGIC CANCER
Endometrium Endogenous Chronic anovulation (PCOS and obesity) means no progesterone in premenopausal women. Obesity:--Adrenal precursors to E1 and E2 --Decreased SHBG --Increased insulin-like GF
GYNECOLOGIC CANCEREndometrium—Risk Factors HNPCC (Lynch Syndrome II) is a mutation of “DNA mismatch repair” genes MLH1, MSH2 & 6, and PMS2 most often.
High risk for tumors of endometrium, ovary, stomach, small bowel, hepato- biliary system, urologic system. In half of the women, endometrial and ovarian cancer PRECEDE colon cancer.
GYNECOLOGIC CANCER
Endometrium HNPCC should be considered if hx of three relatives with colorectal, endometrial, small bowel, urologic system One first degree relative Two successive generations At least one under age 50.
GYNECOLOGIC CANCER
Endometrium
Presentation—Abnormal Bleeding
EVEN ONE DROP OF BLOOD IN A MENOPAUSAL WOMAN NOT ON HORMONES DEMANDS WORKUP
10-20% will have endometrial cancer, and probability increases with age.
GYNECOLOGIC CANCER
Endometrium Screening should be sensitive early in the disease so clinical course can be altered. It should be specific to reduce women needing diagnostic tests. Decreased sensitivity means higher false negativeDecreased specificity means higher false positive
GYNECOLOGIC CANCER
Endometrium Screening Methods: As no reliable,
inexpensive, non invasive method exists, screening in asymptomatic women is not warranted.
90% have abnormal bleeding, and about 70-75% of women are stage I if we test
only after symptoms arise. 5 year survival is 90-95%.
GYNECOLOGIC CANCER
Endometrium Screening Methods Pap is very insensitive Ultrasound is insensitive in asymptomatic women. Endometrial biopsy is sensitive, but invasive, painful, and often QNS for diagnosis. (Recommended by ACS after age 35 for HNPCC, but no data)
GYNECOLOGIC CANCER
Endometrium Variation of screening considerations: Of women with endometrial cancer under age 50, and one first degree relative with HNPCC related cancer, 23% will have a gene mutation and should be screened for that.
(Beware other cancers)
GYNECOLOGIC CANCER
Endometrium—Prevention
Progestin with estrogen
Diet, Exercise and Weight control
If genetic mutation, AND done with reproduction, offer hysterectomy and BSO
GYNECOLOGIC CANCER
Ovary
5% of all cancers in women.
23% of all gynecologic cancer
1.7-2% lifetime risk
GYNECOLOGIC CANCER
Ovary
Ovarian cancer affects females of
ALL AGES
Prognosis depends on cell type, grade and stage.
GYNECOLOGIC CANCER
Ovary
Tissue types
Epithelial—About 85-90% (>50 yrs)
Germ cell—10-15% (<20yrs)
Gonadal stroma—5-10%
Mesenchymal
GYNECOLOGIC CANCER
Ovary
Epithelial
Serous
Mucinous
Endometrioid
Clear cell
Undifferentiated
GYNECOLOGIC CANCER
Ovary Germ Cell Dysgerminoma Endodermal Sinus Embryonal Choriocarcinoma Polyembryoma Immature Teratoma Gonadoblastoma
GYNECOLOGIC CANCER
Ovary
Gonadal Stroma
Granulosa cell
Theca cell
Sertoli-Leydig
GYNECOLOGIC CANCER
Ovary
Mesenchymal
Lymphoma
Sarcoma
GYNECOLOGIC CANCER
Ovary Symptoms are all non specific Abdominal swelling/bloating Abdominal/Pelvic pressure or pain GI upset/dyspepsia Urinary frequency EXAMINE THE PATIENT. Routine CAT scan may take weeks to perform.
GYNECOLOGIC CANCER
Ovary
Cancer should be suspected in any woman between 40 and 80 with persistent gi symptoms cannot be diagnosed.
Diagnosis is difficult. 70% of diagnoses
are stage III or IV.
GYNECOLOGIC CANCER
Ovary Decreased Risk Factors (Prevention) Parity OCPs ??Low fat diet Increased Risk Factors Age Genetic Mutation-- Only 10% of
cancers. (BRCA1 and 2, and HNPCC)
GYNECOLOGIC CANCER
Ovary Decreasing Risk=Prevention
Effect of Parity
Term Pregnancies RR
0 1
1 0.6
2 or 3 0.5
4 or more 0.33
GYNECOLOGIC CANCER
Ovary Decreasing Risk=Prevention
Effect of OCPs
Duration of use RR
Never 1
3mos-4yrs 0.65
5-9 yrs 0.4
10 yrs or more 0.2
GYNECOLOGIC CANCER
Ovary
Increase Risk Factor
BRCA1 35-45%
BRCA2 15-25%
If reproduction is not an issue, offer BSO.
GYNECOLOGIC CANCER
Ovary Screening
There are no reliable data that ANY mode of screening is effective in improving the length and quality of life in women with ovarian cancer.
GYNECOLOGIC CANCER
Ovary Screening -Asymptomatic -Find at early stage -Reasonable return for effort -Reliable tests—sensitivity and specificity
GYNECOLOGIC CANCER
Ovary
Higher SENSITIVITY, lower false neg
Higher SPECIFICITY, lower false pos
GYNECOLOGIC CANCER
Ovary
Screening methods
Pelvic examination
CA-125
Ultrasound
Future use of tumor markers
GYNECOLOGIC CANCER
Ovary
Screening
Pelvic exam—Neither sensitive or
specific. Estimated 10,000 to find 1
early stage ovarian cancer.
GYNECOLOGIC CANCER
Ovary Screening CA-125
Less than 50% of stage I will have
elevated levels and OTHER
conditions raise the CA-125
GYNECOLOGIC CANCER
Ovary Screening CA-125 is elevated Gyn—Endometriosis, adenomyosis,
fibroids, functional ovarian cysts, menstruation, benign neoplasms, PID
Non-Gyn—Liver disease (acute and chronic infectious and alcoholic), pancreatitis, CHF, colitis, diverticulitis, pneumonia, pericarditis, renal disease, SLE and PAN.
GYNECOLOGIC CANCER
Ovary Screening
CA-125 with other tumor markers, particularly HE4, look promising.
As cancers are abnormal cells, they make
abnormal proteins. If patterns can be found that are both sensitive and specific we might have good screening tests. (Proteomics)
GYNECOLOGIC CANCER
Ovary Screening CA-125
Marker Sensitivity Specificity
CA-125 69.5 62
With HE4 73 95
GYNECOLOGIC CANCER
Ovary Screening Ultrasound University of Kentucky **14,500 asymptomatic women **10 yrs **57,200 scans **180 surgical explorations **11 invasive epithelial cancers found. 8 were stage I or IIFOR EACH CANCER FOUND there were 16 surgeries and 5,200 ultrasounds.
GYNECOLOGIC CANCER
Ovary Screening Ultrasound
Largest study to date using COMBINATION. If CA-125 high, had ultrasound.
**41 surgeries
**11 ovarian cancer (4 early stage)
***8 women with negative screens
developed cancer.
GYNECOLOGIC CANCER
Cervix 12% of gynecologic cancers
Mean age is 47. 20% of cases in women >65yrs 10% of cases in women >75yrs
GYNECOLOGIC CANCER
Cervix * Prior to Pap smears, this was the
most common gynecologic cancer worldwide.
*In developed nations, there has been a 75% DECREASE in the past 50 yrs, mainly due to detection and treatment of pre-invasive disease.
GYNECOLOGIC CANCER
Cervix
Types
Squamous Cell 85-90%
Adenocarcinoma 10-15%
Numerous others <5%
GYNECOLOGIC CANCER
Cervix Etiology is oncogenic HPV Risk Factors Early onset coitus Multiple partners, or high risk partner Smoking is co-carcinogen Immunosuppression
GYNECOLOGIC CANCER
Cervix Smoking Effect
Group RR
HPV neg—non smoker 1
Smoker 2
HPV pos 15
HPV pos smoker 66
GYNECOLOGIC CANCER
Cervix Screening—Major methods Pap—Either traditional or liquid based About equal in early stage disease. (60-75% senstivity; 86-100% specific for HSIL) HPV testing Primary screen—being studied. Some studies=100% sens, but LOW specificity. Supplemental to ASCUS Pap, currently
GYNECOLOGIC CANCER
Cervix Screening
Frequency of screening is undergoing continual re-evaluation. There are guidelines, but these must be modified for the individual patient.
GYNECOLOGIC CANCER
Cervix HPV
*80% of sexually active women will
acquire HPV.
*Most will be cleared in 12-18mos
*80-90% will resolve in 2-5yrs.
***Persistence and subtype=cancer.
GYNECOLOGIC CANCER
Cervix HPV
Over 120 types
Oncogenic types: 16, 18, 45, et.al.
Non oncogenic: 6, 11, et.al.
GYNECOLOGIC CANCER
Cervix HPV Oncogenic incorporate into host genome.
Association with SCCaCx 16 60% 18 20% 45 7%
GYNECOLOGIC CANCER
Cervix HPVNon-oncogenic types are associated with formation of condylomata, an emotional and quality of life issue.
Oncogenic virus doesn’t cause condylomata, and non-oncogenic types don’t lead to cancer
GYNECOLOGIC CANCER
Cervix Prevention—Immunization
HPV quadrivalent vaccine contains virons, virus-like particles (NOT live virus) of 6 & 11 (warts), and 16 & 18 (cervical, vaginal and vulvar cancer).
“An ounce of prevention is worth a pound of cure.”
GYNECOLOGIC CANCER
Cervix Prevention—Immunization
In non-exposed individuals, it is 95-100% effective.
If exposed, 80-90% effective, like other vaccines.
GYNECOLOGIC CANCER
Cervix Prevention—Immunization
Cross protection
A strong immune response will cross
protect to related types.
Antibodies to cross protect
16 31, 33, 52, 58
18 39, 45, 59
GYNECOLOGIC CANCER
Cervix Prevention—Immunization
Additional benefits Cancer % HPV related
Anal 70
Vulvar, vag, penile 50
Oropharyngeal 20-40
GYNECOLOGIC CANCER
Cervix Prevention—Immunization
Schedule: Initial, 2mos, 6mos.
Population: Females 9-26 yrs.
*Ongoing studies show effective to give to age 45.
*Effective in males also, but not yet approved.
*Pregnancy Category B
top related